DESCRIPTION
IMMUNITY INDUCTION AGENT
TECHNICAL FIELD
[0001]
The present invention relates to a novel immunity-inducing agent useful as a
therapeutic and/or prophylactic agent for cancer.
BACKGROUND ART
[0002]
Cancer is the commonest cause for death among all of the causes for death,
and therapies carried out therefor at present are mainly surgical treatment, which may
be carried out in combination with radiotherapy and/or chemotherapy. In spite of
the developments of new surgical methods and discovery of new anti-cancer agents
in recent years, treatment results of cancers have not been improved very much so far
except for some cancers. In recent years, by virtue of the development in molecular
biology and cancer immunology, cancer antigens recognized by cytotoxic T cells
reactive with cancers, as well as the genes encoding cancer antigens, were identified,
and expectations for antigen-specific immunotherapies have been raised.
[0003]
In immunotherapy, in order to reduce side effects, the peptide or protein to be
recognized as the antigen needs to be hardly present in normal cells, and to be
specifically present in cancer cells. In 1991, Boon et al. of Ludwig Institute in
Belgium isolated a human melanoma antigen MAGE 1, which is recognized by CD8-
positive T cells, by a cDNA-expression cloning method using an autologous cancer
cell line and cancer-reactive T cells (Non-patent Document 1). Thereafter, the
SEREX (serological identifications of antigens by recombinant expression cloning)
method, wherein tumor antigens recognized by antibodies produced in the living

body of a cancer patient in response to the patient's own cancer are identified by .
application of a gene expression cloning method, was reported (Patent Document 1,
Non-patent Document 2), and several cancer antigens have been isolated by this
method. Using a part of the cancer antigens as targets, clinical tests for cancer
immunotherapy have started.
[0004]
On the other hand, as in human, a number of tumors such as mammary gland
tumor and squamous cell carcinoma are known in dogs and cats, and they rank high
also in the statistics of diseases in dogs and cats. However, no therapeutic agent,
prophylactic agent or diagnostic agent effective for cancers in dogs or cats exists at
present. Since most tumors in dogs and cats are realized by their owners only after
the tumors grew larger due to the progression, their visit to the hospital is already too
late, and even if they receive surgical excision or administration of a human drug (an
anticancer drug or the like), they often die shortly after the treatment. Under such
circumstances, if therapeutic agents and prophylactic agents for cancer effective for
dogs and cats become available, their uses for dog cancers are expected to be
developed.
[0005]
Stearoyl-CoA desaturase 1 (SCD1) introduces a double bond to the C9-C10
position of a saturated fatty acid. Preferred substrates for the enzyme are palmitoyl-
CoA (16:0) and stearoyl-CoA (18:0), and these are converted to palmitoleoyl-CoA
(16:1) and oleoyl-CoA (18:1), respectively. The obtained monounsaturated fatty
acid can then be used in vivo for preparation of phospholipids, triglycerides and
cholesteryl esters. Further, various cancers such as liver cancer, esophagus cancer
and colon cancer show increased expression of SCD1, and it has been reported that
inhibition of the function of SCD1 with siRNA or a low-molecular-weight compound
causes suppression of the cell growth or induction of apoptosis (Non-patent

Documents 3,4 and 5). However, there is no report suggesting that SCD1 protein
has immunity-inducing activity against cancer cells and hence that the protein is
useful for treatment or prophylaxis of cancer.
PRIOR ART DOCUMENTS
[0006]
Patent Document
[Patent Document 1] US 5698396 B
[0007]
Non-patent Documents
[Non-patent Document 1] Bruggen P. et al., Science, 254:1643-1647 (1991)
[Non-patent Document 2] Proc. Natl. Acad. Sci. USA, 92: 11810-11813
(1995)
[Non-patent Document 3] ScagliaN. et al., PLoS One 4: e6812 (2009)
[Non-patent Document 4] Morgan-Lappe SE. et al., Cancer Res 67: 4390-
4398 (2007)
[Non-patent Document 5] Scaglia N. et al., Biochim Biophys Acta 1687: 141-
151(2005)
[Non-patent Document 6] Ariyama H. et al., J Biol Chem (2010)
SUMMARY OF THE INVENTION
PROBLEMS TO BE SOLVED BY THE INVENTION
[0008]
The present invention aims to discover a novel polypeptide useful for a
therapeutic and/or prophylactic agent for cancer, and to provide the polypeptide for
use in an immunity-inducing agent.
MEANS FOR SOLVING THE PROBLEMS
[0009]
By the SEREX method using a dog testis-derived cDNA library and serum

obtained from a tumor-bearing dog, the present inventors intensively studied to
obtain a cDNA encoding a protein which binds to antibodies present in serum
derived from a tumor-bearing living body, and, based on the cDNA, a polypeptide of
dog stearoyl-CoA desaturase 1 (hereinafter referred to as SCD1) having the amino
acid sequence of SEQ ID NO:2 was prepared. Further, based on human and mouse
homologous genes of the obtained gene, human and mouse SCDls having the amino
acid sequences of SEQ ID NOs:4 and 6 were prepared. Further, the present
inventors discovered that these SCD1 polypeptides are specifically expressed in
tissues or cells of breast cancer, brain tumor, colon cancer, perianal adenocarcinoma,
mastocytoma, neuroblastoma, renal cancer, liver cancer, lung cancer, prostate cancer
and leukemia. The present inventors further discovered that administration of the
SCD1 to a living body enables induction of immunocytes against SCD1 in the living
body and regression of a tumor expressing SCD1 in the living body. Further, the
present inventors discovered that a recombinant vector which can express a
polynucleotide encoding the SCD1 polypeptide or a fragment thereof induces an
antitumor effect against cancer expressing SCD1 in a living body.
[0010]
Further, the present inventors discovered that an SCD1 polypeptide has a
capacity to be presented by antigen-presenting cells to cause activation and the
growth of cytotoxic T cells specific to the peptide (immunity-inducing activity), and
therefore that the polypeptide is useful for therapy and/or prophylaxis of cancer.
Further, the present inventors discovered that antigen-presenting cells which have
contacted with the polypeptide, and T cells which have contacted with the antigen-
presenting cells, are useful for therapy and/or prophylaxis of cancer, thereby
completing the present invention.
[0011]
Thus, the present invention has the following characteristics.

(1) An immunity-inducing agent comprising as an effective ingredient(s) at least
one polypeptide having immunity-inducing activity selected from the polypeptides
(a) to (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s)
encoding the at least one polypeptide, the recombinant vector(s) being capable of
expressing the polypeptide(s) in vivo:
(a) a polypeptide composed of not less than 7 consecutive amino acids in any
one of the amino acid sequences of SEQ ID NOs:4,2,22 and 24 in SEQUENCE
LISTING;
(b) a polypeptide having a sequence identity of not less than 85% to the
polypeptide (a) and composed of not less than 7 amino acids; and
(c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence
thereof.

(2) The immunity-inducing agent according to (1), wherein the polypeptide
having immunity-inducing activity is a polypeptide having the amino acid sequence
of SEQ ID NO:4,2,22 or 24 in SEQUENCE LISTING.
(3) The immunity-inducing agent according to (1) or (2), which is an agent for
treating antigen-presenting cells.

(4) The immumty-inducing agent according to (1) or (2), which is a therapeutic
and/or prophylactic agent for a cancer(s).
(5) The immunity-inducing agent according to (4), wherein the cancer(s) is/are a
cancer(s) expressing SCD1.
(6) The immunity-inducing agent according to (4) or (5), wherein the cancer(s)
is/are breast cancer, brain tumor, colon cancer, perianal adenocarcinoma,
mastocytoma, neuroblastoma, renal cancer, liver cancer, lung cancer, prostate cancer
and/or leukemia.
(7) The immunity-inducing agent according to any one of (1) to (6), further
comprising an immunoenhancer.

(8) The immunity-inducing agent according to (7), wherein the immunoenhancer
is at least one selected from the group consisting of Freund's incomplete adjuvant;
Montanide; poly-I:C and derivatives thereof; CpG oligonucleotides; interleukin-12;
interleukin-18; interferon-α; interferon-β; interferon-ω; interferon-γ; and Flt3 ligand.
EFFECT OF THE INVENTION
[0012]
By the present invention, a novel immunity-inducing agent useful for therapy,
prophylaxis and/or the like of cancer is provided. As concretely described in the
later-mentioned Examples, administration of the polypeptide used in the present
invention to a living body enables induction of immunocytes in the living body, and a
cancer which has already occurred can be reduced or regressed. Therefore, the
polypeptide is useful for therapy and/or prophylaxis of cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013]
Fig. 1 shows the expression patterns of the identified SCD1 gene in dog
normal tissues, tumor tissues and cancer cell lines. Reference numeral 1, the
expression patterns of the dog SCD1 gene in various dog tissues and cell lines;
reference numeral 2, the expression patterns of the dog GAPDH gene in various dog
tissues and cell lines.
Fig. 2 shows the expression patterns of the identified SCD1 gene in human
normal tissues, tumor tissues and cancer cell lines. Reference numeral 3, the
expression patterns of the human SCD1 gene in various human tissues and cell lines;
reference numeral 4, the expression patterns of the human GAPDH gene in various
human tissues and cell lines.
Fig. 3 shows the expression patterns of the identified SCD1 gene in mouse
normal tissues, tumor tissues and cancer cell lines. Reference numeral 5, the
expression patterns of the mouse SCD1 gene in various mouse tissues and cell lines;

reference numeral 6, the expression patterns of the mouse GAPDH gene in various
mouse tissues and cell lines.
BEST MODE FOR CARRYING OUT THE INVENTION
[0014]
Examples of the polypeptide contained in the immunity-inducing agent of the
present invention as an effective ingredient include the following. In the present
invention, the term "polypeptide" means a molecule formed by a plurality of amino
acids linked together by peptide bonds, and includes not only polypeptide molecules
having large numbers of amino acids constituting them, but also low-molecular-
weight molecules having small numbers of amino acids (oligopeptides), and full-
length proteins. The present invention also includes the full-length SCD1 proteins
having the amino acid sequence of SEQ ID NO:4,2,22 or 24.
[0015]
(a) A polypeptide that is composed of not less than 7 consecutive amino acids
in a polypeptide having the amino acid sequence of SEQ ID NO:4,2,22 or 24 in
SEQUENCE LISTING, and has an immunity-inducing activity.
(b) A polypeptide composed of not less than 7 amino acids, which
polypeptide has a sequence identity of not less than 85% to the polypeptide (a) and an
immunity-inducing activity.
(c) A polypeptide that comprises the polypeptide (a) or (b) as a partial
sequence thereof, and has an immunity-inducing activity.
[0016]
In the present invention, the term "having an amino acid sequence" means
that amino acid residues are arrayed in such an order. Therefore, for example,
"polypeptide having the amino acid sequence of SEQ ID NO:2" means the
polypeptide having the amino acid sequence of Met Pro Ala His ... (snip)... Tyr Lys
Ser Gly shown in SEQ ID NO:2, which polypeptide has a size of 360 amino acid

residues. Further, for example, "polypeptide having the amino acid sequence of •
SEQ ID NO:2" may be referred to as "polypeptide of SEQ ID NO:2" for short. This
also applies to the term "having a base sequence". In this case, the term "having"
may be replaced with the expression "composed of.
[0017]
As used herein, the term "immunity-inducing activity" means an ability to
induce immunocytes that secrete cytokines such as interferon in a living body.
[0018]
Whether or not the polypeptide has an immunity-inducing activity can be
confirmed using, for example, the known ELISPOT assay. More specifically, for
example, as described in the Examples below, cells such as peripheral blood
mononuclear cells are obtained from a living body subjected to administration of the
polypeptide whose immunity-inducing activity is to be evaluated, and the obtained
cells are then cocultured with the polypeptide, followed by measuring the amount(s)
of a cytokine(s) produced by the cells using a specific antibody/antibodies, thereby
enabling measurement of the number of immunocytes among the cells. By this,
evaluation of the immunity-inducing activity is possible.
[0019]
Alternatively, as described in the later-mentioned Examples, administration of
the recombinant polypeptide of any of (a) to (c) described above to a tumor-bearing
animal allows regression of the tumor by its immunity-inducing activity. Thus, the
above immunity-inducing activity can be evaluated also as an ability to suppress the
growth of cancer cells or to cause reduction or disappearance of a cancer tissue
(tumor) (hereinafter referred to as "antitumor activity"). The antitumor activity of a
polypeptide can be confirmed by, for example, as more specifically described in the
Examples below, observation of whether or not a tumor is reduced when the
polypeptide was actually administered to a tumor-bearing living body.

[0020]
Alternatively, the antitumor activity of a polypeptide can be evaluated also by
observation of whether or not T cells stimulated with the polypeptide (that is, T cells
brought into contact with antigen-presenting cells presenting the polypeptide) show a
cytotoxic activity against tumor cells in vitro. The contact between the T cells and
the antigen-presenting cells can be carried out by their coculture in a liquid medium,
as mentioned below. Measurement of the cytotoxic activity can be carried out by,
for example, the known method called 51Cr release assay described in Int. J. Cancer,
58: p 317,1994. In cases where the polypeptide is to be used for therapy and/or
prophylaxis of cancer, the evaluation of the immunity-inducing activity is preferably
carried out using the antitumor activity as an index, although the index is not limited
thereto.
[0021]
Each of the amino acid sequences of SEQ ID NOs:2,4,22 and 24 in
SEQUENCE LISTING disclosed in the present invention is an amino acid sequence
of SCD1 that was isolated, by the SEREX method using a dog testis-derived cDNA
library and serum of a tumor-bearing dog, as a polypeptide that specifically binds to
an antibody existing in the serum of a tumor-bearing dog, or a homologous factor of
the polypeptide in human, cow or horse (see Example 1). Human SCD1, which is
the human homologous factor of dog SCD1, has a sequence identity of 89% in terms
of the base sequence and 90% in terms of the amino acid sequence; bovine SCD1,
which is the bovine homologous factor, has a sequence identity of 88% in terms of
the base sequence and 87% in terms of the amino acid sequence; and equine SCD1,
which is the equine homologous factor, has a sequence identity of 90% in terms of
the base sequence and 87% in terms of the amino acid sequence.
[0022]
The polypeptide (a) is a polypeptide composed of not less than 7 consecutive,

preferably 8, 9 or not less than 10 consecutive, amino acids in the polypeptide having
the amino acid sequence of SEQ ID NO:2,4,22 or 24, and has an immunity-inducing
activity. The polypeptide is more preferably a polypeptide composed of an amino
acid sequence having a sequence identity of not less than 85% to the amino acid
sequence of SEQ ID NO:4, and the polypeptide especially preferably has the amino
acid sequence of SEQ ID NO:2,4,22 or 24. As is known in the art, a polypeptide
having not less than about 7 amino acid residues can exert its antigenicity and
immunogenicity. Thus, a polypeptide having not less than 7 consecutive amino acid
residues in the amino acid sequence of SEQ ID NO:2,4,22 or 24 can have an
immunity-inducing activity, so that the polypeptide can be used for preparation of the
immunity-inducing agent of the present invention.
[0023]
As a principle of immune induction by administration of a cancer antigenic
polypeptide, the following process is known: a polypeptide is incorporated into an
antigen-presenting cell and then degraded into smaller fragments by peptidases in the
cell, followed by being presented on the surface of the cell. The fragments are then
recognized by a cytotoxic T cell or the like that selectively kills cells presenting the
antigen. The size of the polypeptide presented on the surface of the antigen-
presenting cell is relatively small and about 7 to 30 amino acids. Therefore, from
the viewpoint of presenting the polypeptide on the surface of the antigen-presenting
cell, one preferred mode of the above-described polypeptide (a) is a polypeptide
composed of about 7 to 30 consecutive amino acids in the amino acid sequence of
SEQ ID NO:2,4,22 or 24, and more preferably, a polypeptide composed of about 8
to 30 or about 9 to 30 amino acids is sufficient as the polypeptide (a). In some cases,
these relatively small polypeptides are presented directly on the surface of antigen-
presenting cells without being incorporated into the antigen-presenting cells.
[0024]

Further, a polypeptide incorporated into an antigen-presenting cell is cleaved
at random sites by peptidases in the cell to yield various polypeptide fragments,
which are then presented on the surface of the antigen-presenting cell. Therefore,
administration of a large polypeptide such as the full-length region of SEQ ID NO:2,
4,22 or 24 inevitably causes production of polypeptide fragments by degradation in
the antigen-presenting cell, which fragments are effective for immune induction via
the antigen-presenting cell. Therefore, also for immune induction via antigen-
presenting cells, a large polypeptide can be preferably used, and the polypeptide may
be composed of not less than 30, preferably not less than 100, more preferably not
less than 200, still more preferably not less than 250 amino acids. The polypeptide
may be still more preferably composed of the full-length region of SEQ ID NO:2, 4,
22 or 24.
[0025]
The polypeptide (b) is the same polypeptide as the polypeptide (a) except that
a small number of (preferably, one or several) amino acid residues are substituted,
deleted and/or inserted, which has a sequence identity of not less than 90%,
preferably not less than 95%, more preferably not less than 98%, still more preferably
not less than 99% or not less than 99.5% to the original sequence and has an
immunity-inducing activity. It is well known in the art that, in general, there are
cases where a protein antigen retains almost the same antigenicity as the original
protein even if the amino acid sequence of the protein is modified such that a small
number of amino acid residues are substituted, deleted and/or inserted. Therefore,
since the polypeptide (b) may also exert an immunity-inducing activity, it can be used
for preparation of the immunity-inducing agent of the present invention. Further,
the polypeptide (b) is also preferably a polypeptide having the same amino acid
sequence as the amino acid sequence of SEQ ID NO:2,4,22 or 24 except that one or
several amino acid residues are substituted, deleted and/or inserted. As used herein,

the term "several" means an integer of 2 to 10, preferably an integer of 2 to 6, mord
preferably an integer of 2 to 4.
[0026]
As used herein, the term "sequence identity" of amino acid sequences or base
sequences means the value calculated by aligning two amino acid sequences (or base
sequences) to be compared such that the number of matched amino acid residues (or
bases) is maximum between the amino acid sequences (or base sequences), and
dividing the number of matched amino acid residues (or the number of matched
bases) by the total number of amino acid residues (or the total number of bases),
which value is represented as a percentage. When the alignment is carried out, one
or more gaps are inserted into one or both of the two sequences to be compared as
required. Such alignment of sequences can be carried out using a well-known
program such as BLAST, FASTA or CLUSTAL W. When one or more gaps are
inserted, the above-described total number of amino acid residues is the number of
residues calculated by counting one gap as one amino acid residue. When the thus
counted total number of amino acid residues is different between the two sequences
to be compared, the sequence identity (%) is calculated by dividing the number of
matched amino acid residues by the total number of amino acid residues in the longer
sequence.
[0027]
The 20 types of amino acids constituting naturally occurring proteins may be
classified into groups in each of which similar properties are shared, for example,
into neutral amino acids with side chains having low polarity (Gly, He, Val, Leu, Ala,
Met, Pro), neutral amino acids having hydrophilic side chains (Asn, Gin, Thr, Ser,
Tyr, Cys), acidic amino acids (Asp, Glu), basic amino acids (Arg, Lys, His) and
aromatic amino acids (Phe, Tyr, Trp). It is known that, in many cases, substitution
of an amino acid within the same group does not change the properties of the

polypeptide. Therefore, in cases where an amino acid residue in the polypeptide (a)
of the present invention is substituted, the probability that the immunity-inducing
activity can be maintained may be increased by carrying out the substitution within
the same group, which is preferred.
[0028]
The polypeptide (c) is a polypeptide that comprises the polypeptide (a) or (b)
as a partial sequence and has an immunity-inducing activity. That is, the
polypeptide (c) is a polypeptide in which one or more amino acids and/or one or
more polypeptides is added at one or both ends of the polypeptide (a) or (b), and has
an immunity-inducing activity. Such a polypeptide can also be used for preparation
of the immunity-inducing agent of the present invention.
The above-described polypeptides can be synthesized by, for example, a
chemical synthesis method such as the Fmoc method (fluorenylmethyloxycarbonyl
method) or the tBoc method (t-butyloxycarbonyl method). Further, they can be
synthesized by conventional methods using various types of commercially available
peptide synthesizers. Further, the polypeptide of interest can be obtained using
known genetic engineering techniques by preparing a polynucleotide encoding the
polypeptide and incorporating the polynucleotide into an expression vector, followed
by introducing the resulting vector into a host cell and allowing the host cell to
produce the polypeptide therein.
[0029]
The polynucleotide encoding the above polypeptide can be easily prepared by
a known genetic engineering technique or a conventional method using a
commercially available nucleic acid synthesizer. For example, DNA having the
base sequence of SEQ ID NO:l can be prepared by carrying out PCR using a dog
chromosomal DNA or cDNA library as a template, and a pair of primers designed
such that the base sequence of SEQ ID NO: 1 can be amplified therewith. DNA

having the base sequence of SEQ ID NO:3 can be similarly prepared by using a
human chromosomal DNA or cDNA library as the template. The reaction
conditions for the PCR can be set appropriately, and examples of the reaction
conditions include, but are not limited to, repeating the reaction process of 94°C for
30 seconds (denaturation), 55°C for 30 seconds to 1 minute (annealing) and 72°C for
2 minutes (extension) for, for example, 30 cycles, followed by the reaction at 72°C
for 7 minutes. Further, the desired DNA can be isolated by preparing an appropriate
probe or primer based on the information of the base sequence or the amino acid
sequence of SEQ ID NO:l or 3 in SEQUENCE LISTING in the present description,
and screening a cDNA library of dog, human or the like using the probe or primer.
The cDNA library is preferably prepared from cells, an organ or a tissue expressing
the protein of SEQ ID NO:2 or 4. The above-described operations such as
preparation of the probe or primer, construction of the cDNA library, screening of the
cDNA library and cloning of the gene of interest are known to those skilled in the art,
and can be carried out according to the methods described in Molecular Cloning,
Second Edition; Current Protocols in Molecular Biology; and/or the like. From the
thus obtained DNA, DNA encoding the polypeptide (a) can be obtained. Further,
since the codons encoding each amino acid are known, the base sequence of a
polynucleotide encoding a specific amino acid sequence can be easily specified.
Therefore, since the base sequence of a polynucleotide encoding the polypeptide (b)
or polypeptide (c) can also be easily specified, such a polynucleotide can also be
easily synthesized using a commercially available nucleic acid synthesizer according
to a conventional method.
[0030]
The host cells are not restricted as long as the cells can express the above-
described polypeptide, and examples of the cells include, but are not limited to,
prokaryotic cells such as E. coli; and eukaryotic cells such as mammalian cultured

cells including monkey kidney cells COS1 and Chinese hamster ovary cells CHO;-
budding yeast; fission yeast; silkworm cells; and Xenopus laevis egg cells.
[0031]
In cases where prokaryotic cells are used as the host cells, an expression
vector containing an origin that enables replication of the vector in a prokaryotic cell,
promoter, ribosome binding site, DNA cloning site, terminator and/or the like is used.
Examples of the expression vector for E. coli include the pUC system, pBluescriptll,
pET expression system and pGEX expression system. By incorporating a DNA
encoding the above polypeptide into such an expression vector and transforming
prokaryotic host cells with the vector, followed by culturing the resulting
transformants, the polypeptide encoded by the DNA can be expressed in the
prokaryotic host cells. In such a case, the polypeptide can also be expressed as a
fusion protein with another protein.
[0032]
In cases where eukaryotic cells are used as the host cells, an expression vector
for eukaryotic cells, comprising a promoter, splicing site, poly(A) addition site and/or
the like is used as the expression vector. Examples of such an expression vector
include pKA1, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV vector,
pRS, pcDNA3, pMSG and pYES2. Similarly to the above case, by incorporating a
DNA encoding the above polypeptide into such an expression vector and
transforming eukaryotic host cells with the vector, followed by culturing the resulting
transformants, the polypeptide encoded by the DNA can be expressed in the
eukaryotic host cells. In cases where pIND/V5-His, pFLAG-CMV-2, pEGFP-N1,
pEGFP-C1 or the like is used as the expression vector, the above polypeptide can be
expressed as a fusion protein comprising a tag such as a His tag, FLAG tag, myc tag,
HA tag or GFP.
[0033]

For the introduction of the expression vector into host cells, a well-known,
method such as electroporation, the calcium phosphate method, the liposome method
or the DEAE dextran method may be used.
[0034]
Isolation and purification of the polypeptide of interest from the host cells can
be carried out by a combination of known separation operations. Examples of the
known separation operations include, but are not limited to, treatment with a
denaturant such as urea or with a surfactant; ultrasonication treatment; enzyme
digestion; salting-out or solvent fractional precipitation; dialysis; centrifugation;
ultrafiltration; gel filtration; SDS-PAGE; isoelectric focusing; ion-exchange
chromatography; hydrophobic chromatography; affinity chromatography; and
reversed-phase chromatography.
[0035]
The polypeptides obtained by the above methods also include, as mentioned
above, those in the form of a fusion protein with another arbitrary protein.
Examples of such polypeptides include fusion proteins with glutathion S-transferase
(GST) and fusion proteins with a His tag. Such a polypeptide in the form of a
fusion protein is also included within the scope of the present invention as the above-
described polypeptide (c). Further, in some cases, the polypeptide expressed in a
transformed cell is modified in various ways in the cell after translation. Such a
post-translationally modified polypeptide is also included within the scope of the
present invention as long as it has an immunity-inducing activity. Examples of such
a post-translational modification include: elimination of N-terminal methionine; N-
terminal acetylation; glycosylation; limited degradation by an intracellular protease;
myristoylation; isoprenylation; and phosphorylation.
[0036]
As described more concretely in the later-mentioned Examples,

administration of the polypeptide having an immunity-inducing activity to a tumor-
bearing living body enables regression of an already existing tumor. Therefore, the
immunity-inducing agent of the present invention can be used as a therapeutic and/or
prophylactic agent for cancer. Further, the polypeptide having an immunity-
inducing activity can be used for a method of therapy and/or prophylaxis of cancer by
immune induction.
[0037]
As used herein, the terms "tumor" and "cancer" mean a malignant neoplasm,
and are used interchangeably
[0038]
In this case, the cancer to be treated is not restricted as long as SCD1 is
expressed in the cancer, and the cancer is preferably breast cancer, brain tumor, colon
cancer, perianal adenocarcinoma, mastocytoma, neuroblastoma, renal cancer, liver
cancer, lung cancer, prostate cancer or leukemia.
[0039]
The subject animal is preferably a mammal, more preferably a mammal such
as a primate, pet animal, domestic animal or sport animal, especially preferably
human, dog or cat.
[0040]
The administration route of the immunity-inducing agent of the present
invention to a living body may be either oral administration or parenteral
administration, and is preferably parenteral administration such as intramuscular
administration, subcutaneous administration, intravenous administration or
intraarterial administration. In cases where the immunity-inducing agent is used for
therapy of cancer, it may be administered to a regional lymph node in the vicinity of
the tumor to be treated, as described in the Examples below, in order to enhance its
anticancer activity. The dose may be any dose as long as the dose is effective for

immune induction, and, for example, in cases where the agent is used for therapy .
and/or prophylaxis of cancer, the dose may be one effective for therapy and/or
prophylaxis of the cancer. The dose effective for therapy and/or prophylaxis of
cancer is appropriately selected depending on the size, symptoms and the like of the
tumor, and the effective dose is usually 0.0001 µg to 1000 µg, preferably 0.001 µg to
1000 µg per subject animal per day. The agent may be administered once, or
dividedly in several times. The agent is preferably administered dividedly in several
times, every several days to several months. As concretely shown in the Examples
below, the immunity-inducing agent of the present invention can cause regression of
an already occurred tumor. Therefore, since the agent can exert its anticancer
activity also against a small number of cancer cells at an early stage, development or
recurrence of cancer can be prevented by using the agent before development of the
cancer or after therapy for the cancer. That is, the immunity-inducing agent of the
present invention is effective for both therapy and prophylaxis of cancer.
[0041]
The immunity-inducing agent of the present invention may contain only a
polypeptide or may be formulated by being mixed as appropriate with an additive
such as a pharmaceutically acceptable carrier, diluent or vehicle suitable for each
administration mode. Formulation methods and additives which may be used are
well-known in the field of formulation of pharmaceuticals, and any of the methods
and additives may be used. Specific examples of the additives include, but are not
limited to, diluents such as physiological buffer solutions; vehicles such as sugar,
lactose, corn starch, calcium phosphate, sorbitol and glycine; binders such as syrup,
gelatin, gum arabic, sorbitol, polyvinyl chloride and tragacanth; and lubricants such
as magnesium stearate, polyethylene glycol, talc and silica. Examples of the
formulation include oral preparations such as tablets, capsules, granules, powders and
syrups; and parenteral preparations such as inhalants, injection solutions,

suppositories and solutions. These formulations may be prepared by commonly •
known production methods.
[0042]
The immunity-inducing agent of the present invention may be used in
combination with an immunoenhancer capable of enhancing the immune response in
a living body. The immunoenhancer may be contained in the immunity-inducing
agent of the present invention or administered as a separate composition to a patient
in combination with the immunity-inducing agent of the present invention.
[0043]
Examples of the immunoenhancer include adjuvants. Adjuvants can
enhance the immune response by providing a reservoir of antigen (extracellularly or
inside macrophages), activating macrophages and stimulating specific sets of
lymphocytes, thereby enhancing the immune response and hence the anticancer
action. Therefore, especially in cases where the immunity-inducing agent of the
present invention is used for therapy and/or prophylaxis of cancer, the immunity-
inducing agent preferably comprises an adjuvant, in addition to the above-described
polypeptide as an effective ingredient. Many types of adjuvants are well known in
the art, and any of these adjuvants may be used. Specific examples of the adjuvants
include MPL (SmithKline Beecham), homologues of Salmonella minnesota Re 595
lipopolysaccharide obtained after purification and acid hydrolysis of the
lipopolysaccharide; QS21 (SmithKline Beecham), pure QA-21 saponin purified from
an extract of Quillja saponaria; DQS21 described in PCT application WO 96/33739
(SmithKline Beecham); QS-7, QS-17, QS-18 and QS-L1 (So and 10 colleagues,
"Molecules and cells", 1997, Vol. 7, p. 178-186); Freund's incomplete adjuvant;
Freund's complete adjuvant; vitamin E; Montanide; alum; CpG oligonucleotides (see,
for example, Kreig and 7 colleagues, Nature, Vol. 374, p. 546-549); poly-I:C and
derivatives thereof (e.g., poly ICLC); and various water-in-oil emulsions prepared

from biodegradable oils such as squalene and/or tocopherol. Among these,
Freund's incomplete adjuvant; Montanide; poly-I:C and derivatives thereof; and CpG
oligonucleotides are preferred. The mixing ratio between the above-described
adjuvant and the polypeptide is typically about 1:10 to 10:1, preferably about 1:5 to
5:1, more preferably about 1:1. However, the adjuvant is not limited to the above-
described examples, and adjuvants known in the art other than those described above
may also be used when the immunity-inducing agent of the present invention is
administered (see, for example, Goding, "Monoclonal Antibodies: Principles and
Practice, 2nd edition", 1986). Preparation methods for mixtures or emulsions of a
polypeptide and an adjuvant are well known to those skilled in the art of vaccination.
[0044]
Further, in addition to the above-described adjuvants, factors that stimulate
the immune response of the subject may be used as the above-described
immunoenhancer. For example, various cytokines having a property to stimulate
lymphocytes and/or antigen-presenting cells may be used as the immunoenhancer in
combination with the immunity-inducing agent of the present invention. A number
of such cytokines capable of enhancing the immune response are known to those
skilled in the art, and examples of the cytokines include, but are not limited to,
interleukin-12 (IL-12), GM-CSF, IL-18, interferon-α, interferon-β, interferon-ω,
interferon-γ, and Flt3 ligand, which have been shown to enhance the prophylactic
action of vaccines. Such factors may also be used as the above-described
immunoenhancer, and may be contained in the immunity-inducing agent of the
present invention, or may be prepared as a separate composition to be administered to
a patient in combination with the immunity-inducing agent of the present invention.
[0045]
By bringing the above-described polypeptide into contact with antigen-
presenting cells in vitro, the antigen-presenting cells can be made to present the

polypeptide. That is, the polypeptides (a) to (c) described above can be used as .
agents for treating antigen-presenting cells. Examples of the antigen-presenting
cells which may be preferably used include dendritic cells and B cells having MHC
class I molecules. Various MHC class I molecules have been identified and are
well-known. MHC molecules in human are called HLA. Examples of HLA class
I molecules include HLA-A, HLA-B and HLA-C, more specifically, HLA-A1, HLA-
A0201, HLA-A0204, HLA-A0205, HLA-A0206, HLA-A0207, HLA-A11, HLA-A24,
HLA-A31, HLA-A6801, HLA-B7, HLA-B8, HLA-B2705, HLA-B37, HLA-Cw0401
andHLA-Cw0602.
[0046]
The dendritic cells or B cells having MHC class I molecules can be prepared
from peripheral blood by a well-known method. For example, tumor-specific
dendritic cells can be induced by inducing dendritic cells from bone marrow,
umbilical cord blood or patient's peripheral blood using granulocyte-macrophage
colony-stimulating factor (GM-CSF) and IL-3 (or IL-4), and then adding a tumor-
related peptide to the culture system.
[0047]
By administering an effective amount of such dendritic cells, a response
desired for therapy of a cancer can be induced. As the cells, bone marrow or
umbilical cord blood donated by a healthy individual, or bone marrow, peripheral
blood or the like of the patient may be used. When autologous cells of the patient
are used, high safety can be attained and serious side effects are expected to be
avoided. The peripheral blood or bone marrow may be any of a fresh sample, cold-
stored sample and cryopreserved sample. As for the peripheral blood, whole blood
may be cultured or the leukocyte components alone may be separated and cultured,
and the latter is more efficient and thus preferred. Further, among the leukocyte
components, mononuclear cells may be separated. In cases where the cells are

originated from bone marrow or umbilical cord blood, the whole cells constituting,
the bone marrow may be cultured, or mononuclear cells may be separated therefrom
and cultured. Peripheral blood, the leukocyte components thereof and bone marrow
cells contain mononuclear cells, hematopoietic stem cells and immature dendritic
cells, from which dendritic cells are originated, and also CD4-positive cells and the
like. The production method for the cytokine is not restricted, and a naturally-
occurring or recombinant cytokine or the like may be employed as long as its safety
and physiological activity have been confirmed. Preferably, a preparation with
assured quality for medical use is used in the minimum necessary amount. The
concentration of the cytokine(s) to be added is not restricted as long as the dendritic
cells are induced at the concentration, and usually, the total concentration of the
cytokine(s) is preferably about 10 to 1000 ng/mL, more preferably about 20 to 500
ng/mL. The culture may be carried out using a well-known medium usually used
for culture of leukocytes. The culturing temperature is not restricted as long as
proliferation of leukocytes is possible at the temperature, and a temperature of about
37°C, which is the body temperature of human, is most preferred. The atmospheric
environment during the culture is not restricted as long as proliferation of the
leukocytes is possible under the environment, and the culture is preferably performed
under a flow of 5% CO2. The culturing period is not restricted as long as a
necessary number of the cells are induced, and usually 3 days to 2 weeks. As for the
apparatuses used for separation and culturing of the cells, appropriate apparatuses,
preferably those whose safety upon application to medical uses have been confirmed
and whose operations are stable and simple, may be employed. In particular,
examples of the cell-culturing apparatus include not only general vessels such as
Petri dishes, flasks and bottles, but also layer-type vessels, multistage vessels, roller
bottles, spinner-type bottles, bag-type culturing vessels and hollow fiber columns.
[0048]

The method per se to be used for bringing the above-described polypeptide
into contact with the antigen presenting cells in vitro may be those well known in the
art. For example, the antigen-presenting cells may be cultured in a culture medium
containing the above-described polypeptide. The concentration of the peptide in the
medium is not restricted, and usually about 1 to 100 µg/ml, preferably about 5 to 20
µg/ml. The cell density during the culture is not restricted and usually about 103 to
107 cells/ml, preferably about 5 × 104 to 5 × 106 cells/ml. The culture is preferably
carried out according to a conventional method at 37°C under the atmosphere of 5%
CO2. The maximum length of the peptide which can be presented on the surface of
the antigen-presenting cells is usually about 30 amino acid residues. Therefore, in
cases where the antigen-presenting cells are brought into contact with the polypeptide
in vitro, the polypeptide may be prepared such that its length is not more than about
30 amino acid residues, although the length is not restricted.
[0049]
By culturing the antigen-presenting cells in the coexistence of the above-
described polypeptide, the polypeptide is incorporated into MHC molecules of the
antigen-presenting cells and presented on the surface of the antigen-presenting cells.
Therefore, using the above-described polypeptide, isolated antigen-presenting cells
containing the complex between the polypeptide and the MHC molecule can be
prepared. Such antigen-presenting cells can present the polypeptide against T cells
in vivo or in vitro, to induce, and allow proliferation of, cytotoxic T cells specific to
the polypeptide.
[0050]
By bringing the thus prepared antigen-presenting cells having the complex
between the above-described polypeptide and the MHC molecule into contact with T
cells in vitro, cytotoxic T cells specific to the polypeptide can be induced and
allowed to proliferate. This may be carried out by coculturing the above-described

antigen-presenting cells and T cells in a liquid medium. For example, the antigen-
presenting cells may be suspended in a liquid medium and placed in a vessel such as
a well of a microplate, followed by adding T cells to the well and then performing
culture. The mixing ratio of the antigen-presenting cells to the T cells in the
coculture is not restricted, and usually about 1:1 to 1:100, preferably about 1:5 to
1:20 in terms of the cell number. The density of the antigen-presenting cells to be
suspended in the liquid medium is not restricted, and usually about 100 to 10,000,000
cells/ml, preferably about 10,000 to 1,000,000 cells/ml. The coculture is preferably
carried out by a conventional method at 37°C under the atmosphere of 5% CO2.
The culturing period is not restricted, and usually 2 days to 3 weeks, preferably about
4 days to 2 weeks. The coculture is preferably carried out in the presence of one or
more interleukins such as IL-2, IL-6, IL-7 and/or IL-12. In such cases, the
concentration of IL-2 or IL-7 is usually about 5 to 20 U/ml, the concentration of IL-6
is usually about 500 to 2000 U/ml, and the concentration of IL-12 is usually about 5
to 20 ng/ml, but the concentrations of the interleukins are not restricted thereto. The
above coculture may be repeated once to several times with addition of fresh antigen-
presenting cells. For example, the operation of discarding the culture supernatant
after the coculture and adding a fresh suspension of antigen-presenting cells to
further conduct the coculture may be repeated once to several times. The conditions
for each coculture may be the same as those described above.
[0051]
By the above-described coculture, cytotoxic T cells specific to the polypeptide
are induced and allowed to proliferate. Thus, using the above-described polypeptide,
isolated T cells can be prepared which selectively bind to the complex between the
polypeptide and the MHC molecule.
[0052]
As described in the Examples below, the SCD1 gene is expressed specifically

in breast cancer cells, breast cancer tissues, brain tumor cells, brain tumor tissues, •
colon cancer cells, colon cancer tissues, perianal adenocarcinoma tissues, perianal
adenocarcinoma cells, mastocytoma tissues, mastocytoma cells, neuroblastoma cells,
renal cancer cells, renal cancer tissues, liver cancer cells, liver cancer tissues, lung
cancer cells, lung cancer tissues, prostate cancer cells, prostate cancer tissues and
leukemia cells. Therefore, it is thought that, in these cancer species, a significantly
larger amount of SCD1 exists than in normal cells. When the thus prepared
cytotoxic T cells are administered to a living body such that a part of the SCD1
polypeptide present in cancer cells is presented by MHC molecules on the surface of
the cancer cells, the cytotoxic T cells can damage the cancer cells using the presented
polypeptide as a marker. Since the antigen-presenting cells presenting a part of the
above-described SCD1 polypeptide can induce, and allow proliferation of, cytotoxic
T cells specific to the polypeptide also in vivo, cancer cells can be damaged also by
administering the antigen-presenting cells to a living body. That is, the cytotoxic T
cells and the antigen-presenting cells prepared using the polypeptide are also
effective as therapeutic and/or prophylactic agents for cancer, similarly to the
immunity-inducing agent of the present invention.
[0053]
In cases where the above-described isolated antigen-presenting cells or
isolated T cells are administered to a living body, these are preferably prepared by
treating antigen presenting cells or T cells collected from the patient to be treated,
using the polypeptide (a), (b) or (c) as described above in order to avoid the immune
response in the living body that attacks these cells as foreign bodies.
[0054]
The therapeutic and/or prophylactic agent for cancer comprising as an
effective ingredient the antigen-presenting cells or T cells is preferably administered
via a parenteral administration route, for example, by intravenous or intraarterial

administration. The dose is appropriately selected depending on the symptoms, the
purpose of administration and the like, and is usually 1 cell to 10,000,000,000,000
cells, preferably 1,000,000 cells to 1,000,000,000 cells, which dose is preferably
administered once every several days to once every several months. The
formulation may be, for example, the cells suspended in physiological buffered saline,
and the formulation may be used in combination with another/other anticancer
preparation(s) and/or cytokine(s). Further, one or more additives well known in the
field of formulation of pharmaceuticals may also be added.
[0055]
Also by expressing a polynucleotide encoding any of the polypeptides (a) to
(c) in the body of the subject animal, antibody production and cytotoxic T cells can
be induced in the living body, and an effect comparable to that obtained in the case of
administration of the polypeptide can be obtained. That is, the immunity-inducing
agent of the present invention may be one comprising as an effective ingredient a
recombinant vector having a polynucleotide encoding any of the polynucleotides (a)
to (c), which recombinant vector is capable of expressing the polypeptide in a living
body. Such a recombinant vector capable of expressing an antigenic polypeptide as
shown in the later-mentioned Examples is also called a gene vaccine.
[0056]
The vector used for production of the gene vaccine is not restricted as long as
it is a vector capable of expressing the polypeptide in a cell of the subject animal
(preferably in a mammalian cell), and may be either a plasmid vector or a virus
vector, and any known vector in the field of gene vaccines may be used. The
polynucleotide such as DNA or RNA encoding the above-described polypeptide can
be easily prepared as mentioned above by a conventional method. Incorporation of
the polynucleotide into the vector can be carried out using a method well known to
those skilled in the art.

[0057]
The administration route of the gene vaccine is preferably a parenteral route
such as intramuscular, subcutaneous, intravenous or intraarterial administration.
The dose may be appropriately selected depending on the type of the antigen and the
like, and is usually about 0.1 ug to 100 mg, preferably about 1 ug to 10 mg in terms
of the weight of the gene vaccine per kg body weight.
[0058]
Examples of the method using a virus vector include those wherein a
polynucleotide encoding the above-described polypeptide is incorporated into an
RNA virus or DNA virus, such as a retrovirus, adenovirus, adeno-associated virus,
herpes virus, vaccinia virus, pox virus, polio virus or Sindbis virus, and then a subject
animal is infected with the resulting virus. Among these methods, those using a
retrovirus, adenovirus, adeno-associated virus, vaccinia virus or the like are
especially preferred,
[0059]
Examples of other methods include a method wherein an expression plasmid
is directly intramuscularly administered (DNA vaccine method), and the liposome
method, lipofectin method, microinjection method, calcium phosphate method and
electroporation method. The DNA vaccine method and liposome method are
especially preferred.
[0060]
Methods for making the gene encoding the above-described polypeptide used
in the present invention actually act as a pharmaceutical include in vivo methods
wherein the gene is directly introduced into the body, and ex vivo methods wherein a
certain kind of cells are collected from the subject animal and the gene is then
introduced into the cells ex vivo, followed by returning the cells to the body (Nikkei
Science, 1994, April, p. 20-45; The Pharmaceutical Monthly, 1994, Vol. 36, No. 1, p.

23-48; Experimental Medicine, Extra Edition, 1994, Vol.12, No. 15; and references
cited in these literatures, and the like). The in vivo methods are more preferred.
[0061]
In cases where the gene is administered by an in vivo method, the gene may
be administered through an appropriate administration route depending on the
disease to be treated, symptoms and the like. The gene may be administered by, for
example, intravenous, intraarterial, subcutaneous or intramuscular administration.
In cases where the gene is administered by an in vivo method, the gene may be
formulated into a preparation such as a solution, and in general, it is formulated into
an injection solution or the like containing DNA encoding the above-described
peptide of the present invention as an effective ingredient. A commonly used
carrier may be also added thereto as required. In cases of a liposome or membrane
fusion liposome (Sendai virus (HVJ)-liposome or the like) containing the DNA, the
liposome may be formulated into a liposome preparation such as a suspension, frozen
preparation or centrifugally concentrated frozen preparation.
[0062]
In the present invention, "the base sequence of SEQ ID NO:l" includes not
only the actual base sequence of SEQ ID NO:l, but also the sequence complementary
thereto. Thus, "the polynucleotide having the base sequence of SEQ ID NO: 1"
includes the single-stranded polynucleotide having the actual base sequence of SEQ
ID NO:l, the single-stranded polynucleotide having the base sequence
complementary thereto, and the double-stranded polynucleotide composed of these
single-stranded polynucleotides. When a polynucleotide encoding the polypeptide
used in the present invention is prepared, any one of these base sequences is
appropriately selected, and those skilled in the art can easily carry out the selection.
EXAMPLES
[0063]

The present invention will now be described more concretely by way of •
Examples.
[0064]
Example 1: Obtaining Novel Cancer Antigen Protein by SEREX Method
(1) Preparation of cDNA Library
Total RNA was extracted from testis of a dog by the acid-guanidium-phenol-
chloroform method, and poly(A) RNA was purified using Oligotex-dT30 niRNA
purification Kit (manufactured by Takara Shuzo Co., Ltd.) in accordance with the
protocol attached to the kit.
[0065]
Using the obtained mRNA (5 ug), a cDNA phage library was synthesized.
For the preparation of a cDNA phage library, cDNA Synthesis Kit, Zap-cDNA
Synthesis Kit, and ZAP-cDNA Gigapack III Gold Cloning Kit (manufactured by
STRATAGENE) were used in accordance with the protocols attached to the kits.
The size of the prepared cDNA phage library was 1 x 106pfu/ml.
[0066]
(2) Screening of cDNA Library with Serum
Using the thus prepared cDNA phage library, immunoscreening was carried
out. More specifically, the host E. coli (XL 1 -Blue MRF') was infected with the
library such that 2340 clones appeared on an NZY agarose plate with a size of 90 mm
dia. x 15 mm, and cultured at 42°C for 3 to 4 hours to allow the phage to form
plaques. The plate was covered with a nitrocellulose membrane (Hybond C Extra:
manufactured by GE Healthcare Bio-Science) impregnated with IPTG (isopropyl-P-
D-thiogalactoside) at 37°C for 4 hours to allow induction and expression of proteins,
and the proteins were transferred onto the membrane. Subsequently, the membrane
was recovered and soaked in TBS (10 mM Tris-HCl, 150 mM NaCl; pH 7.5)
supplemented in 0.5% non-fat dry milk. The membrane was then shaken at 4°C

overnight to suppress non-specific reactions. This filter was then allowed to react
with 500-fold diluted dog patient serum at room temperature for 2 to 3 hours.
[0067]
As the above-described dog patient serum, serum collected from a dog patient
with a perianal tumor was used. The serum was stored at -80°C and pretreated
immediately before use. The method of the pretreatment of serum was as follows.
That is, the host E. coli (XLl-Blue MRF') was infected with X ZAP Express phage
having no foreign gene inserted, and then cultured on NZY plate medium at 37°C
overnight. Subsequently, 0.2 M NaHCC<3 buffer (pH 8.3) supplemented with 0.5 M
NaCl was added to the plate, and the plate was left to stand at 4°C for 15 hours,
followed by collecting the supernatant as an E. co///phage extract. Thereafter, the
collected E. co///phage extract was passed through an NHS-column (manufactured by
GE Healthcare Bio-Science) to immobilize proteins derived from the E. co/z/phage
thereon. The serum from the dog patient was passed through, and reacted with, this
protein-immobilized column to remove antibodies that adsorb to E. coli and/or the
phage. The serum fraction that passed through the column was 500-fold diluted
with TBS supplemented with 0.5% non-fat dry milk, and the resulting diluent was
used as the material for the immunoscreening.
[0068]
The membrane on which the thus treated serum and the above-described
fusion protein were blotted was washed 4 times with TBS-T (0.05% Tween 20/TBS),
and reacted with goat anti-dog IgG (Goat anti Dog IgG-h+I HRP conjugated:
manufactured by BETHYL Laboratories) 5,000-fold diluted with TBS supplemented
with 0.5% non-fat dry milk as a secondary antibody at room temperature for 1 hour,
followed by detection by enzyme coloring reaction using an NBT/BCIP reaction
solution (manufactured by Roche). Colonies at positions corresponding to coloring-
reaction-positive sites were recovered from the NZY agarose plate having a size of

90 mm dia. × 15 mm, and dissolved in 500 µl of SM buffer (100 mM NaCl, 10 mM
MgClSO4, 50 mM Tris-HCl, 0.01 % gelatin; pH 7.5). The screening was repeated as
the second and third screening in the same manner as described above until a single
coloring-reaction-positive colony was obtained. The isolation of the single positive
clone was achieved after screening of 9110 phage clones reactive with IgG in the
serum.
[0069]
(3) Sequence Homology Search of Isolated Antigen Gene
To subject the single positive clone isolated by the above-described method to
base sequence analysis, an operation of conversion of the phage vector to a plasmid
vector was carried out. More specifically, 200 µl of a solution prepared such that
the host E. coli (XLl-Blue MRF') was contained at an absorbance OD600 of 1.0 was
mixed with 100 ul of a purified phage solution and further with 1 ul of ExAssist
helper phage (manufactured by STRATAGENE), and the reaction was then allowed
to proceed at 37°C for 15 minutes. This was followed by addition of 3 ml of LB
medium to the reaction mixture, and culture was performed with the resulting
mixture at 37°C for 2.5 to 3 hours. The resulting culture was immediately
incubated in a water bath at 70°C for 20 minutes. The culture was then centrifuged
at 4°C at 1,000 xg for 15 minutes, and the supernatant was recovered as a phagemid
solution. Subsequently, 200 ul of a solution prepared such that the phagemid host E.
coli (SOLR) was contained at an absorbance OD600 of 1.0 was mixed with 10 µl of a
purified phage solution, and the reaction was allowed to proceed at 37°C for 15
minutes. Thereafter, 50 ul of the reaction mixture was plated on LB agar medium
supplemented with ampicillin (final concentration: 50 ug/ml), and culture was
performed at 37°C overnight. A single colony of transformed SOLR was recovered
and cultured in LB medium supplemented with ampicillin (final concentration: 50
µg/ml) at 37°C, followed by purification of plasmid DNA having the insert of interest

using QIAGEN plasmid Miniprep Kit (manufactured by Qiagen).
[0070]
The purified plasmid was subjected to analysis of the full-length sequence of
the insert by the primer walking method using the T3 primer of SEQ ID NO:7 and
the T7 primer of SEQ ID NO:8. By this sequence analysis, the gene sequence of
SEQ ID NO: 1 was obtained. Using the base sequence and the amino acid sequence
of this gene, homology search against known genes was carried out using a sequence
homology search program BLAST (http://www.ncbi.nlm.nih.gov/BLAST/). As a
result, it was revealed that the obtained gene is the SCD1 gene. Human SCD1,
which is a human homologous factor of dog SCD1, had a sequence identity of 89%
in terms of the base sequence and 90% in terms of the amino acid sequence; mouse
SCD1, which is a mouse homologous factor, had a sequence identity of 84% in terms
of the base sequence and 84% in terms of the amino acid sequence. The base
sequence and the amino acid sequence of human SCD1 are shown in SEQ ID NO:3
and SEQ ID NO:4, respectively, and the base sequence and the amino acid sequence
of mouse SCD1 are shown in SEQ ID NO:5 and SEQ ID NO:6, respectively.
[0071]
(4) Analysis of Expression in Various Tissues
Expression of the genes obtained by the above method in dog, human and
mouse normal tissues and various cell lines were investigated by the RT-PCR
(Reverse Transcription-PCR) method. The reverse transcription reaction was
carried out as follows. That is, from 50 to 100 mg of each tissue or 5 × 106 to 10 ×
106 cells of each cell line, total RNA was extracted using the TRIZOL reagent
(manufactured by Invitrogen) according to the protocol described in the attached
instructions. Using this total RNA, cDNA was synthesized with the Superscript
First-Strand Synthesis System for RT-PCR (manufactured by Invitrogen) according
to the protocol described in the attached instructions. As the cDNAs of human

normal tissues (brain, hippocampus, testis, colon and placenta), Gene Pool cDNA-
(manufactured by Invitrogen), QUICK-Clone cDNA (manufactured by
CLONETECH) and Large-Insert cDNA Library (manufactured by CLONETECH)
were used. The PCR reaction was carried out using primers specific to the obtained
gene (the dog primers shown in SEQ ID NOs:9 and 10, the human primers shown in
SEQ ID NOs:l 1 and 12, and the mouse primers shown in SEQ ID NOs:13 and 14) as
described below. That is, the reagents and the attached buffer were mixed such that
0.25 µl of the sample prepared by the reverse transcription reaction, 2 uM each of the
above primers, 0.2 mM each of dNTPs, and 0.65 U ExTaq polymerase (manufactured
by Takara Shuzo Co., Ltd.) were contained in the resulting mixture in a final volume
of 25 ul, and the reaction was carried out by 30 cycles of 94°C for 30 seconds, 55°C
for 30 seconds and 72°C for 1 minute using a Thermal Cycler (manufactured by BIO
RAD). As a control for comparison, primers specific to GAPDH (the dog and
human GAPDH primers are shown in SEQ ID NOs:15 and 16; and the mouse
GAPDH primers are shown in SEQ ID NOs:17 and 18) were used at the same time.
As a result, as shown in Fig. 1, the dog SCD1 gene was not expressed in most of the
healthy dog tissues, while the gene was strongly expressed in the dog tumor tissues.
Also in terms of the human and mouse SCD1 genes, the expression was not observed
in most of the normal human and mouse tissues, while the expression was detected in
most of the cancer cell lines (Figs. 2 and 3), as in the case of the dog SCD1 gene.
[0072]
(5) Quantitative Analysis of Expression in Various Tissues
The gene obtained by the above method was subjected to investigation of
expression in human normal tissues by the quantitative RT-PCR (Reverse
Transcription-PCR) method. As cDNAs for human normal tissues and cancer
tissues, Tissue scan Real Time cancer survey Panel I (manufactured by ORIGENE)
was used. The quantitative RT-PCR was carried out using CFX96 Real Time

Cystem - CI000 Thermal Cycler, manufactured by Bio-Rad Laboratories, Inc. The
PCR reaction was carried out as follows using primers specific to the obtained gene
(shown in SEQ ED NOs: 11 and 12). That is, 5 ul of the cDNA sample, 2 uM each
of the primers, and the reagents and the buffer contained in 2× SYBR Premix Ex
Taqll polymerase (manufactured by Takara Shuzo Co., Ltd.) were mixed together to
prepare a mixture in a final volume of 20 ul, and the reaction was carried out by 30
cycles of 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute. As a
result, the expression level of the SCD1 gene in each of breast cancer, colon cancer,
renal cancer, liver cancer, prostate cancer and lung cancer was not less than 4 times
higher than the expression level in its corresponding normal tissue. Based on these
results, it can be expected that there is no concern of occurrence of side effects by
antitumor agents targeting human SCD1 in normal tissues at all, and that the benefit
of the pharmacological effect of the agents largely exceeds the risk of their side
effects.
[0073]
Example 2: Analysis of Cancer Antigenicity of SCD1 in Vivo
(l)Preparation of Recombinant Vector That Expresses SCD1 in Vivo
Based on the base sequence of SEQ ID NO:5, a recombinant vector that
expresses SCD1 in vivo was prepared. PCR was prepared from the mouse cancer
cell line N2a (purchased from ATCC), which showed the expression in Example 1.
The reagents and the attached buffer were mixed such that 1 ul of the cDNA, 0.4 uM
each of two kinds of primers having the HindIII and XbaI restriction sites (shown in
SEQ ID NOs: 19 and 20), 0.2 mM dNTP and 1.25 U PrimeSTAR HS polymerase
(manufactured by Takara Shuzo Co., Ltd.) were contained in the resulting mixture in
a final volume of 50 ul, and PCR was carried out by 30 cycles of 98°C for 10 seconds,
55°C for 15 seconds and 72°C for 4 minute using a Thermal Cycler (manufactured by
BIO RAD). The above-described two kinds of primers were those for amplification

of the region encoding the full-length of the amino acid sequence of SEQ ID NO:5.
After the PCR, the amplified DNA was subjected to electrophoresis using 1%
agarose gel, and a DNA fragment of about 1000 bp was purified using QIAquick Gel
Extraction Kit (manufactured by QIAGEN).
[0074]
The purified DNA fragment was ligated into a cloning vector pCR-Blunt
(manufactured by Invitrogen). E. coli was transformed with the resulting ligation
product, and the plasmid was then recovered. The sequence of the amplified gene
fragment was confirmed to be the same as the sequence of interest by sequencing.
The plasmid having the sequence of interest was treated with restriction enzymes
HindIII aadXbaI, and purified using QIAquick Gel Extraction Kit, followed by
inserting the gene sequence of interest into a mammalian expression vector
pcDNA3.1 (manufactured by Invitrogen) that had been treated with the restriction
enzymes i/wdIII and XbaI. Use of this vector enables production of SCD1 protein
in mammalian cells.
[0075]
To 100 ug of the thus prepared plasmid DNA, 50 fig of gold particles
(manufactured by Bio Rad), 100 ul of spermidine (manufactured by SIGMA) and 100
ul of 1 M CaCl2 (manufactured by SIGMA) were added, and the resulting mixture
was stirred by vortexing, followed by leaving the mixture to stand for 10 minutes at
room temperature (the resulting particles are hereinafter referred to as the gold-DNA
particles). The mixture was then centrifuged at 3000 rpm for 1 minute and the
supernatant was discarded, followed by rinsing the precipitate 3 times with 100%
ethanol (manufactured by WAKO). To the gold-DNA particles, 6 ml of 100%
ethanol was added, and the resulting mixture was sufficiently stirred by vortexing,
followed by pouring the gold-DNA particles into Tefzel Tubing (manufactured by
Bio Rad) and allowing the particles to precipitate on the wall surface. Ethanol was

removed by air-drying from the Tefzel Tubing to which the gold-DNA particles were
attached, and the tube was then cut into pieces having a length that is appropriate for
a gene gun.
[0076]
(2) Antitumor Effect of SCD1 by DNA Vaccine Method
The above prepared tube was fixed in a gene gun, and the DNA vaccine was
transdermally administered, by application of a pressure of 400 psi using pure helium
gas, a total of 3 times at intervals of 7 days to the abdominal cavity of each of 10
individuals of A/J mice (7 weeks old, male, purchased from Japan SLC) and Balb/c
mice (7 weeks old, male, purchased from Japan SLC) whose hair had been shaved
(this corresponds to inoculation of 2 µg/individual of the plasmid DNA). Thereafter,
a mouse neuroblastoma cell line N2a or a colon cancer cell line CT26 was
transplanted to each mouse in an amount of 1 × 106 cells to evaluate the antitumor
effect (prophylactic model). For each model, plasmid DNA containing no SCD1
gene inserted was administered to 10 individuals of mice to provide a control.
[0077]
The antitumor effect was evaluated based on the size of the tumor (major axis
x minor axis / 2) and the ratio of living mice. As a result of this study, in the
prophylactic model using the neuroblastoma cell line, the size of the tumor became
2966 mm3 and 759 mm3 on Day 43 in the control group and the SCD1 plasmid-
administered group, respectively. Thus, remarkable regression of the tumor was
observed in the SCD1 plasmid-administered group. Further, as a result of
observation of survival in the prophylactic model using the neuroblastoma cell line, it
was found that all cases died by Day 74 after the administration in the control group,
while 60% of the mice survived in the SCD1 plasmid-administered group. These
results indicate a significant antitumor effect in the SCD1 plasmid-administered
group as compared to the control group. Similarly, in the prophylactic model using

the colon cancer cell line, the size of the tumor became 2518 mm and 604 mm on
Day 33 in the control group and the SCD1 plasmid-administered group, respectively.
Thus, remarkable regression of the tumor was observed in the SCD1 plasmid-
administered group. Further, as a result of observation of survival, it was found that
all cases died by Day 54 after the administration in the control group, while 50% of
the mice survived in the SCD1 plasmid-administered group. These results indicate
a significant antitumor effect in the SCD1 plasmid-administered group as compared
to the control group.
[0078]
Example 3: Preparation of Human Recombinant SCD1 Protein and Evaluation of Its
Immunity-inducing Ability
(1) Preparation of Human Recombinant SCD1 Protein
Based on the base sequence of SEQ ID NO:3, a recombinant protein of
human SCD1 was prepared. The regents and the attached buffer were mixed such
that 1 ul of the cDNA prepared in Example 1 whose expression could be confirmed
for cDNAs from various tissues and cells by the RT-PCR method, 0.4 uM each of
two kinds of primers having the EcoRI andXhoI restriction sites (shown in SEQ ID
NOs:25 and 26), 0.2 mM dNTP and 1.25 U PrimeSTAR HS polymerase
(manufactured by Takara Shuzo Co., Ltd.) were contained in the resulting mixture in
a final volume of 50 ul, and PCR was carried out by 30 cycles of 98°C for 10 seconds,
55°C for 15 seconds and 72°C for 4 minute using a Thermal Cycler (manufactured by
BIO RAD). The above-described two kinds of primers were those for amplification
of the region encoding the full-length of the amino acid sequence of SEQ ID NO:4.
After the PCR, the amplified DNA was subjected to electrophoresis using 1%
agarose gel, and a DNA fragment of about 1000 bp was purified using QIAquick Gel
Extraction Kit (manufactured by QIAGEN).
[0079]

The purified DNA fragment was ligated into a cloning vector pCR-Blunt .
(manufactured by Invitrogen). E. coli was transformed with the resulting ligation
product, and the plasmid was then recovered. The sequence of the amplified gene
fragment was confirmed to be the same as the sequence of interest by sequencing.
The plasmid having the sequence of interest was treated with restriction enzymes
EcoRI aad Xhol, and purified using QIAquick Gel Extraction Kit, followed by
inserting the gene sequence of interest into an expression vector for E. coli, pET30a
(manufactured by Novagen) that had been treated with the restriction enzymes EcoKL
and Xhol. Use of this vector enables production of a His tag-fused recombinant
protein. E. coli for expression, BL21 (DE3), was transformed with this plasmid,
and expression was induced with 1 mM IPTG, to allow expression of the protein of
interest in E. coli.
[0080]
(2) Purification of Recombinant SCD1 Protein
The thus obtained recombinant E. coli that expresses SEQ ID NO:4 was
cultured in LB medium supplemented with 100 ng/ml ampicillin at 37°C until the
absorbance at 600 nm reached about 0.7, and isopropyl-P-D-1-thiogalactopyranoside
was then added to the culture at a final concentration of 1 mM, followed by further
culturing the recombinant E. coli at 37°C for 4 hours. Subsequently, the bacterial
cells were collected by centrifugation at 4,800 rpm for 10 minutes. The pellet of the
bacterial cells was suspended in phosphate-buffered saline and further subjected to
centrifugation at 4,800 rpm for 10 minutes, to wash the bacterial cells.
[0081]
The bacterial cells were suspended in 50 mM Tris-HCl buffer (pH 8.0) and
subjected to sonication on ice. The liquid obtained by the sonication of E. coli was
centrifuged at 6000 rpm for 20 minutes, to obtain the supernatant as the soluble
fraction and the precipitate as the insoluble fraction.

[0082]
The insoluble fraction was suspended in 50 mM Tris-HCl buffer (pH 8.0) and
then centrifuged at 6000 rpm for 15 minutes. This operation was repeated twice for
removal of proteases.
[0083]
The residue was suspended in 50 mM Tris-HCl buffer (pH 8.0) supplemented
with 6 M guanidine hydrochloride and 0.15 M sodium chloride, and left to stand at
4°C for 20 hours to denature protein. Thereafter, the suspension was centrifuged at
6000 rpm for 30 minutes, and the obtained soluble fraction was placed in a nickel
chelate column prepared by a conventional method (carrier: Chelating Sepharose
(trademark) Fast Flow (GE Health Care); column volume: 5 mL; equilibration buffer:
50 mM Tris-HCl buffer (pH 8.0) supplemented with 6M guanidine hydrochloride and
0.15 M sodium chloride), followed by leaving the resultant to stand at 4°C overnight
to allow adsorption to the nickel-chelated carrier. The column carrier was
centrifuged at 1500 rpm for 5 minutes and the resulting supernatant was recovered.
The column carrier was then suspended in phosphate-buffered saline and refilled into
the column.
[0084]
The fraction not adsorbed to the column was washed with 10 column volumes
of 0.1 M acetate buffer (pH 4.0) supplemented with 0.5 M sodium chloride, and
immediately thereafter, elution with 0.1 M acetate buffer (pH 3.0) supplemented with
0.5 M sodium chloride was carried out to obtain a purified fraction, which was used
later as the material for an administration test. The presence of the protein of
interest in each eluted fraction was confirmed by Coomassie staining carried out
according to a conventional method.
[0085]
The buffer of the purified preparation obtained by the above method was

replaced with a reaction buffer (50 mM Tris-HCl, 100 mM NaCl, 5 mM CaCl2
(pH8.0)), and the resulting sample was subjected to cleavage of the His tag with
factor Xa protease and purification of the protein of interest, using Factor Xa
Cleavage Capture Kit (manufactured by Novagen) in accordance with the protocol
attached to the kit. Subsequently, the buffer of 12 ml of the purified preparation
obtained by the above method was replaced with physiological phosphate buffer
(manufactured by Nissui Pharmaceutical) using ultrafiltration NANOSEP 10K
OMEGA (manufactured by PALL), and the resulting sample was subjected to aseptic
filtration through HT Tuffryn Acrodisc 0.22 µm (manufactured by PALL) and used
in the experiment.
[0086]
(3) Induction of CD8-positive Cytotoxic T Cells Reactive with Human Recombinant
SCD1 Protein
From a healthy individual, peripheral blood was separated, and the peripheral
blood was overlaid on Lymphocyte separation medium (OrganonpTeknika, Durham,
NC), followed by centrifuging the resultant at 1,500 rpm at room temperature for 20
minutes. A fraction containing peripheral blood mononuclear cells (PBMCs) was
recovered and washed 3 (or more) times in cold phosphate buffer, to obtain PBMCs.
The obtained PBMCs were suspended in 20 ml of AIM-V medium (Life
Technololgies, Inc., Grand Island, NY, USA), and the cells were allowed to adhere to
a culture flask (Falcon) at 37°C in 5% CO2 for 2 hours. Nonadherent cells were
used for preparation of T cells, and adherent cells were used for preparation of
dendritic cells.
[0087]
On the other hand, the adherent cells were cultured in AIM-V medium in the
presence of IL-4 (1000 U/ml) and GM-CSF (1000 U/ml). Nonadherent cells
obtained 6 days later were collected, and the human recombinant SCD1 protein was

added to the cells at a concentration of 10 µg/ml, followed by culturing the cells at
37°C in 5% CO2 for 4 hours. Thereafter, the medium was replaced with AIM-V
medium supplemented with IL-4 (1000 U/ml), GM-CSF (1000 U/ml), IL-6 (1000
U/ml, Genzyme, Cambridge, MA), IL-1β (10 ng/ml, Genzyme, Cambridge, MA) and
TNF-a (10 ng/ml, Genzyme, Cambridge, MA), and the culture was carried out for
additional 2 days to obtain a population of nonadherent cell to be used as dendritic
cells.
[0088]
The prepared dendritic cells were suspended in AIM-V medium at a cell
density of 1 × 106 cells/ml, and the human recombinant SCD1 protein was added
again at a concentration of 10 ng/ml to the suspension. Using a 96-well plate, the
cells were cultured at 37°C in 5% CO2 for 4 hours. After the culture, X-ray
irradiation (3000 rads) was carried out, and the cells were washed with AIM-V
medium, followed by suspension in AIM-V medium supplemented with 10% human
AB serum (Nabi, Miami, FL), IL-6 (1000 U/ml) and IL-12 (10 ng/ml, Genzyme,
Cambridge, MA). The cells were then placed in a 24-well plate in an amount of
1 x 105 cells/well. Further, the prepared T cell population was added to each well in
an amount of 1 × 106 cells, and cultured at 3 7°C in 5% CO2. Each culture
supernatant was discarded 7 days later, and dendritic cells obtained in the same
manner as described above by treatment with the human SCD1 protein and the
subsequent X-ray irradiation were suspended in AIM-V medium supplemented with
10% human AB serum (Nabi, Miami, FL), IL-7 (10 U/ml, Genzyme, Cambridge,
MA) and IL-2 (10 U/ml, Genzyme, Cambridge, MA) (cell density, 1 × 105 cells/ml).
The resulting suspension was added to the 24-well plate in an amount of 1 × 105
cells/well, and the cells were further cultured. After repeating the same operation 4
to 6 times at intervals of 7 days, stimulated T cells were recovered, and induction of
CD8-positive T cells was confirmed by flow cytometry.

[0089]
As a negative control, a protein having a sequence that is outside the scope of
the present invention was used (SEQ ID NO:27).
[0090]
Subsequently, whether or not the CD8-positive T cells stimulated with the
present polypeptide can damage SCD1-expressing tumor cells was studied.
[0091]
In a 50-ml centrifuge tube, 105 cells of a human glioma cell line, U-87MG
(purchased from ATCC), in which expression of SCD1 was confirmed, were
collected, and 100 uCi chromium 51 was added to the cells, followed by incubation
of the resulting mixture at 37°C for 2 hours. Thereafter, the cells were washed 3
times with AIM-V medium supplemented with 10% human AB serum, and placed in
a 96-well V-bottom plate in an amount of 103 cells per well. Subsequently, 105,
5×104,2.5×l04 or 1.25×104 CD8-positive T cells that were stimulated with the
human recombinant SCD1 protein and suspended in AIM-V medium supplemented
with 10% human AB serum were added to each well, and culture was performed at
37°C in 5% CO2 for 4 hours. Thereafter, the amount of chromium 51 released from
damaged tumor cells in the culture supernatant was measured using a gamma counter
to calculate the cytotoxic activity of the CD8-positive T cells stimulated with the
human recombinant SCD1 protein.
[0092]
As a result, it was found that the CD8-positive T cells stimulated with the
human recombinant SCD1 protein had cytotoxic activity against U-87MG. On the
other hand, the CD8-positive T cells induced using the negative control protein (SEQ
ID NO:27) did not show cytotoxic activity. Thus, it was revealed that the human
recombinant SCD1 protein used in the present invention has a capacity to induce
CD8-positive cytotoxic T cells that can damage tumor cells.

[0093]
The cytotoxic activity means the cytotoxic activity of the CD8-positive T cells
against T98G determined by: mixing 105 CD8-positive T cells stimulated and
induced as described above, with 103 cells of the malignant brain tumor cell line U-
87MG into which chromium 51 was incorporated; culturing the resulting mixture for
4 hours; measuring the amount of chromium 51 released to the medium after the
culture; and then performing calculation according to Equation 1.
[0094]
Equation 1: Cytotoxic activity (%) = amount of chromium 51 released from U-87MG
after addition of CD8-positive T cells (cpm) / amount of chromium 51 released from
target cells after addition of 1 N hydrochloric acid (cpm) × 100.
INDUSTRIAL APPLICABILITY
[0095]
The present invention is useful for therapy and/or prophylaxis of cancer since
the present invention provides an immunity-inducing agent containing a polypeptide
that exerts antitumor activity against various cancers.

We Claim:
1. An immunity-inducing agent comprising as an effective ingredient(s) at least
one polypeptide having immunity-inducing activity selected from the polypeptides
(a) to (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s)
encoding said at least one polypeptide, said recombinant vector(s) being capable of
expressing said polypeptide(s) in vivo:
(a) a polypeptide composed of not less than 7 consecutive amino acids in any
one of the amino acid sequences of SEQ ID NOs:4,2,22 and 24 in SEQUENCE
LISTING;
(b) a polypeptide having a sequence identity of not less than 85% to said
polypeptide (a) and composed of not less than 7 amino acids; and
(c) a polypeptide comprising said polypeptide (a) or (b) as a partial sequence
thereof.
2. The immunity-inducing agent according to claim 1, wherein said polypeptide
having immunity-inducing activity is a polypeptide having the amino acid sequence
of SEQ ID NO:4,2,22 or 24 in SEQUENCE LISTING.
3. The immunity-inducing agent according to claim 1 or 2, which is an agent for
treating antigen-presenting cells.
4. The immunity-inducing agent according to claim 1 or 2, which is a
therapeutic and/or prophylactic agent for a cancer(s).
5. The immunity-inducing agent according to claim 4, wherein said cancer(s)
is/are a cancer(s) expressing SCD1.
6. The immunity-inducing agent according to claim 4 or 5, wherein said
cancer(s) is/are breast cancer, brain tumor, colon cancer, perianal adenocarcinoma,
neuroblastoma, mastocytoma, renal cancer, liver cancer, lung cancer, prostate cancer
and/or leukemia.
7. The immunity-inducing agent according to any one of claims 1 to 6, further

comprising an immunoenhancer.
8. The immunity-inducing agent according to claim 7, wherein said
immunoenhancer is at least one selected from the group consisting of Freund's
incomplete adjuvant; Montanide; poly-I:C and derivatives thereof; CpG
oligonucleotides; interleukin-12; interleukin-18; interferon-a; interferdn-β;
interferon-ω; interferon-γ; and Flt3 ligand.